



Oxford Brain Diagnostics has started a project for **Takeda Pharmaceuticals**.

The project is testing Cortical Disarray Measurement (CDM[®]) technology as a neurodegeneration biomarker with a view to using it in future clinical trials.

Dr Steven Chance, CEO, said 'we are very excited to be engaged with Takeda on this project using our CDM method on diffusion MRI scans. Alzheimer's remains a complex condition so exploring the disease earlier in patients and focussing on the cortical micro-structure offers a new angle on the problem. Not only does this innovative approach put a spotlight on the search for the best measurement of neurodegeneration but we believe it advances the transformative role that neuroimaging can play in offering specific biomarkers to measure trial endpoints. We expect to publish the results of this project with Takeda in due course.'



Precision measurement of Neurodegeneration.